Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration – Pipeline Review, H1 2017, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape.
Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Juvenile Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 5 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Juvenile Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Acucela Inc
Alkeus Pharmaceuticals Inc
Astellas Pharma Inc
Copernicus Therapeutics Inc
Grupo Ferrer Internacional SA
Iris Pharma
Sanofi
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Juvenile Macular Degeneration (Stargardt Disease) – Overview
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Juvenile Macular Degeneration (Stargardt Disease) – Companies Involved in Therapeutics Development
Acucela Inc
Alkeus Pharmaceuticals Inc
Astellas Pharma Inc
Copernicus Therapeutics Inc
Grupo Ferrer Internacional SA
Iris Pharma
Sanofi
Juvenile Macular Degeneration (Stargardt Disease) – Drug Profiles
ALK-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
echothiophate iodide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emixustat hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAB-111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy 1 to Activate ABCA4 for Stargardt Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBS-008 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA09-hRPE – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate ABCA4 for Stargardt Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ramiprilat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-422459 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
soraprazan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Ophthalmic Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-200 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Juvenile Macular Degeneration (Stargardt Disease) – Dormant Projects
Juvenile Macular Degeneration (Stargardt Disease) – Product Development Milestones
Featured News & Press Releases
Jan 26, 2017: Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease
Jan 05, 2017: Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease
May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease
Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt’s Macular Degeneration Phase 1 Trial in the United Kingdom
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials
Jun 03, 2013: Oxford BioMedica Halts Recruitment Into Phase I/IIa Study Of StarGen
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells
Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration
Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy
Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells
Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Acucela Inc, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Alkeus Pharmaceuticals Inc, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Astellas Pharma Inc, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Copernicus Therapeutics Inc, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Grupo Ferrer Internacional SA, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Iris Pharma, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Sanofi, H1 2017
Juvenile Macular Degeneration (Stargardt Disease) – Dormant Projects, H1 2017
List of Figures
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
